|
Originally published In Press as doi:10.1074/jbc.M103280200 on May 30, 2001
J. Biol. Chem., Vol. 276, Issue 30, 28068-28074, July 27, 2001
Receptor Proximity, Not Intermolecular Orientation, Is Critical
for Triggering T-cell Activation*
Jennifer R.
Cochran,
Thomas O.
Cameron,
Jennifer D.
Stone,
Jodi B.
Lubetsky , and
Lawrence J.
Stern§
From the Department of Chemistry, Massachusetts Institute of
Technology, Cambridge, Massachusetts 02139
Received for publication, April 12, 2001, and in revised form, May 18, 2001
 |
ABSTRACT |
Engagement of antigen receptors on the surface of
T-cells with peptides bound to major histocompatibility complex (MHC)
proteins triggers T-cell activation in a mechanism involving receptor
oligomerization. Receptor dimerization by soluble MHC oligomers is
sufficient to induce several characteristic activation processes in
T-cells including internalization of engaged receptors and
up-regulation of cell surface proteins. In this work, the influence of
intermolecular orientation within the activating receptor dimer was
studied. Dimers of class II MHC proteins coupled in a variety of
orientations and topologies each were able to activate
CD4+ T-cells, indicating that triggering was not
dependent on a particular receptor orientation. In contrast to the
minimal influence of receptor orientation, T-cell triggering was
affected by the inter-molecular distance between MHC molecules, and MHC
dimers coupled through shorter cross-linkers were consistently more
potent than those coupled through longer cross-linkers. These results
are consistent with a mechanism in which intermolecular receptor
proximity, but not intermolecular orientation, is the key determinant
for antigen-induced CD4+ T-cell activation.
 |
INTRODUCTION |
Helper (CD4+) T-cells play a key role in the adaptive
immune response, by detecting and responding to foreign antigens bound to class II major histocompatibility complex
(MHC)1 proteins found on the
surface of B cells, macrophages, and other specialized antigen
presenting cells of the immune system (1). T-cells express on their
surface clonotypic antigen receptors (TCR), which bind complexes of MHC
protein and specific antigenic peptides (2). TCR engagement by
MHC-peptide complexes induces T-cell signaling cascades. Once
triggered, helper T-cells elicit a variety of characteristic processes,
including cytokine secretion, up-regulation of adhesion and
costimulatory molecules, and T-cell proliferation, which leads to
activation of effector functions in antigen presenting cells,
recruitment of other immune cells, and eventually to clearance of the
foreign material (3-5). Some characteristic T-cell activation
responses can be triggered by soluble agents that multivalently engage
TCR, including anti-TCR antibodies (6, 7) and oligomeric MHC-peptide
complexes (reviewed in Ref. 8). Monomeric reagents generally are not
able to induce a response in T-cells, although some exceptions have
been reported, particularly for CD8+ T-cells (7, 9). These
considerations have led to the understanding that T-cells can be
triggered by oligomerization of their surface TCR, although the full
cellular activation response requires additional (co-stimulatory)
signals from the antigen-presenting cell in addition to the antigenic
signal transduced by the TCR (10).
Several studies have pointed to formation of a TCR dimer as the key
event for triggering T-cell activation. Quantitative analyses of the
dependence of T-cell activation on the surface density of MHC-peptide
complexes presented on the surface antigen presenting cells (11, 12) or
incorporated into planar lipid bilayers (13), have suggested a crucial
role of dimer formation in triggering a T-cell response. For soluble
class II MHC oligomers, the minimal MHC valency required to initiate
signaling in CD4+ T-cells appears to be a dimer (14, 15).
Higher valency MHC oligomers can activate more potently than dimers,
but this is due only to their increased binding avidity (15).
The mechanism by which dimerization of TCR triggers cytoplasmic
signaling cascades is unknown. Receptor dimerization as the proximal
activating stimulus is consistent with several potential molecular
mechanisms, including formation of a specific TCR dimer in an
activating conformation (as observed for receptor tyrosine kinases
(16)), molecular rearrangement of a pre-existing receptor dimer (as
observed for the bacterial aspartate receptor (17)), or nonspecific
co-localization of receptor cytoplasmic domains (18). Experimental
discrimination between these potential mechanisms can be difficult, and
recent evidence has suggested that some systems originally thought to
occur through a mechanism of receptor oligomerization may in fact
involve allosteric rearrangements in a pre-existing receptor oligomer
(reviewed in Ref. 19). In support of a nonspecific dimerization model,
T-cell activation has been induced by many different anti-receptor
antibodies (6, 7), and by oligomerization of a variety of chimeric TCR
cytoplasmic domains (20-22). The exact stoichiometry of the unliganded
form of the TCR complex is unknown, but has been proposed to contain two  TCRs (23-25), raising the possibility that molecular
rearrangement of a pre-existing receptor oligomer may be a potential
activation mechanism. However, it is possible that the presence of two
antigen-binding domains could serve only to facilitate the large-order
clustering and oligomerization of receptors on the cell-surface that
has been observed physiologically (26).
To investigate these possible mechanisms, dimeric
MHC-peptide complexes were prepared in a variety of intermolecular
orientations and topologies, and used to probe the effects of receptor
orientation and topology on T-cell triggering. Receptor orientation was
not critical for T-cell signaling, as a variety of conformationally constrained MHC dimers coupled through either the - or -subunit each were able to induce T-cell activation processes. However, efficient T-cell triggering was dependent on receptor proximity, as
activation was diminished when MHC dimers were coupled through longer
cross-links. Collectively, these results suggest that T-cells are
triggered by a mechanism of generalized intermolecular receptor proximity that does not depend on the intermolecular receptor orientation.
 |
EXPERIMENTAL PROCEDURES |
HLA-DR1 Expression and Folding--
HLA-DR1 (A*0101, B1*0101)
- and -subunits, or modified versions carrying a C-terminal
cysteine residue (Cys , Cys) (27), were expressed
as insoluble inclusion bodies in E. coli BL21(DE3) cells as
described (28). Subunits included the peptide binding and
membrane-proximal immunoglobulin domains ( 1-182 and 1-190). In
some experiments a longer version of the -subunit
( L-Cys) was used, which included also the "connecting
peptide" 191-198 (RSESAQSK). Recombinant MHC-peptide complexes
were folded by dilution of urea-solubilized subunits in the presence of
peptide and redox buffers, and isolated by ion-exchange chromatography,
as previously described (28). HLA-DR1 complexes carried antigenic
peptide Ha (resiudes 306-318) (PKYVKQNTLKLAT), derived from
influenza virus hemagglutinin (29), or control endogenous peptide A2
(residues 103-117) (VGSDWRFLRGYHQYA), derived from class I MHC HLA-A2
(30). HLA-DR1 used in preparation of MHC dimers carried a cysteine
residue at either the or C terminus. To prevent oxidation of
the introduced cysteine residues, MHC-peptide complexes containing
introduced cysteines were purified in 5 mM dithiothreitol,
which was removed immediately prior to cross-linking. The introduced
cysteines undergo facile reaction with thiol-specific reagents,
allowing specific cross-linking at the - or -subunit termini.
Synthesis of Cross-linking Reagents--
Polypeptide-based
cross-linkers were synthesized by Fmoc chemistry on a solid-phase
peptide synthesizer as previously described (27) and verified by
matrix-assisted laser desorption ionization-time of flight mass
spectrometry. All cross-linker peptides were capped at their N
termini by reaction with fluorescein isothiocyanate. To introduce
thiol-reactive maleimide groups, purified peptides (2-5 mg) were
reacted through their lysine -amino groups with N-( -maleimidocaproyloxy)succinimide ester (Pierce), by
dissolving 5-fold molar excess in N,N-dimethylformamide and
adding it to peptide in 10 mM Na-phosphate buffer (pH 7),
150 mM NaCl. After 1.5 h at room temperature, the
modified peptides were purified by reverse phase high performance
liquid chromatography using a C18 column (Vydac), and the presence of
both maleimide functional groups was confirmed by matrix-assisted laser
desorption ionization-time of flight mass spectrometry.
Dimerization of MHC-Peptide Complexes--
For direct disulfide
bond formation between the introduced thiols, 0.25 mM
CuSO4 and 1.3 mM 1,10-phenanthroline
(Sigma-Aldrich) were added to MHC-peptide complexes in 50 mM HEPES, (pH 8) (31), for at least 1 h at room
temperature. For dimerization through the thiol-reactive maleimide
groups on the synthetic peptide-based cross-linkers X3X, X9X, and X14X
(Fig. 1A), the cross-linker was added in small batches to
MHC-peptide complexes in 10 mM Na-phosphate (pH 7), 150 mM NaCl, 5 mM EDTA over ~5 h at room
temperature, to a final cross-linker:MHC ratio of 1:2. Cross-linked
MHC-peptide complexes were isolated by gel filtration chromatography on
Superdex-200, using two HR 10/30 FPLC columns (Amersham Pharmacia
Biotech) linked in series. The integrity of covalent thiol linkages and
the presence of bound antigenic peptide were confirmed by SDS-PAGE
(12.5%). Maleimide-to-maleimide distances for cross-linkers in
extended conformations were estimated using molecular models.
Hydrodynamic studies of MHC-Peptide Dimers--
Apparent
Mr (Mr,app)
values for MHC-peptide dimers were determined from elution volumes
obtained by gel filtration chromatography, by reference to a
calibration curve obtained from the elution volume of known
Mr standards (Bio-Rad). The Stokes radii
(RS) of the MHC dimers were derived from the
Mr,app as previously described (32), except the
following equation was used to calculate the hydrated volume
(VH),
|
(Eq. 1)
|
where hydprotein is the estimated extent of
hydration in the protein (0.35 g of water/g of protein),
water is the density of water at 20 °C (0.998 g/cm3), N is Avogadro's number, and psv is the
partial specific volume of HLA-DR1-Ha (0.738 cm3/g)
calculated from the amino acid composition. Confidence intervals (± ) reported in Table I reflect the standard deviation from the
mean of replicate samples in separate experiments.
T-cell Lines--
HA1.7 (33) is a well studied human
CD4+ T-cell clone that responds to the Ha peptide bound to
HLA-DR1. The HLA-DR1-restricted, Ha peptide-specific polyclonal T-cell
line (designated 1H) was raised from the mononuclear cell fraction of
peripheral blood from an HLA-DR1 homozygous individual, by repeated
in vitro stimulation with Ha peptide. HA1.7 and 1H were
maintained in RPMI containing 5% human AB serum (Sigma-Aldrich) and
5% fetal bovine serum (Sigma-Aldrich), with antigenic stimulation
every 2 weeks using 120 IU/ml IL-2 (BIOSOURCE) and
an irradiated mixture of nonspecific peripheral blood lymphocytes and
EBV1.24, a DR1+ B-cell line, pulsed with 1 µM
Ha peptide. T-cells were rested for a minimum of 7 days after
stimulation before use in activation and binding assays.
T-cell Activation Assays--
Soluble MHC-peptide complexes were
added to 5 × 104 T-cells in complete medium in
round-bottom polypropylene 96-well plates. After the desired incubation
time at 37 °C and 7% CO2, cells were placed on ice and
levels of cell surface markers were determined using the following
fluorescent monoclonal antibodies: phycoerythrin (PE)-labeled anti-CD3
(clone UCHT-1, Pharmingen), or allophycocyanin (APC)-labeled anti-CD25
(M-A251, Pharmingen), APC-anti-CD69 (FN50, Pharmingen), and
APC-anti-CD71 (T56/14, Leinco Technologies). After 1 h at 4 °C,
cells were washed with phosphate-buffered saline containing 1% fetal
bovine serum and 0.1% sodium azide, and analyzed by flow cytometry.
Fluorescence data were obtained with a Becton-Dickinson FACS Calibur
flow cytometer and analyzed using Cell Quest software. The number of
CD3 molecules per cell was determined from the mean PE fluorescence
using SPHERO rainbow calibration particles (Spherotech) containing
known amounts of PE equivalents. Experiment to experiment variation was
observed in the overall time course and extent of activation, which
appeared to be dependent on the length of time the T-cells had been in
culture, but relative levels of activation induced by the various
dimers were the same in different experiments.
Competitive Binding Assays--
Competitive binding assays were
performed as previously described (15, 27). Phycoerythrin-labeled,
streptavidin-coupled MHC oligomers (SA-PE), prepared by binding
biotinylated MHC monomers to streptavidin preparations (34), were used
as a binding probe, with competition by unlabeled or
fluorescein-labeled MHC-peptide oligomers. These SA-PE oligomers
exhibit a strong fluorescence from the R-phycoerythrin conjugate and
bind to T-cells in an antigen-specific manner (34). Various
concentrations of MHC dimers and monomer were incubated with a constant
amount of SA-PE oligomer ([MHC]= 4 µg/ml) and 5 × 104 HA1.7 T-cells in 96-well round-bottomed plates for
3 h at 37 °C, 7% CO2. Cells were washed and
fluorescence arising from bound SA-PE oligomer was measured by flow
cytometry as described above.
 |
RESULTS |
MHC-Peptide Dimers--
To investigate the orientation
requirements of T-cell triggering, we prepared soluble dimers of the
human class II MHC protein HLA-DR1, with a variety of different
intermolecular orientations and conformational constraints. The
oligomerization strategy involved specific cross-linking at the
sulfhydryl moiety of a cysteine residue introduced either at the C
terminus of the -subunit immunoglobulin domain ( 182), the C
terminus of the -subunit immunoglobulin domain ( 190), or after
the -subunit connecting peptide region ( 191-198), which
immediately precedes the native transmembrane domain (Fig.
1B). Proteins carrying the
introduced cysteine residues (Cys ,
 Cys, or  L-Cys, respectively) were
produced by in vitro folding in the presence of antigenic
(Ha) or endogenous (A2) peptides, using previously described protocols
(27, 28). MHC-peptide complexes were dimerized either by using a direct
disulfide bond between the introduced cysteine thiols (31), or using a
sulfhydryl-reactive synthetic cross-linking reagent of varying length
(Fig. 1A). The synthetic cross-linkers X3X, X9X, and X14X
are based on a flexible peptide scaffold containing glycine, serine,
and glutamic acid residues, and each carry an N-terminal fluorophore
and two maleimidylcaproyl (X) groups, attached as amides to lysine
residues. MHC-peptide dimers coupled by direct disulfide bonds (S-S) or
by the synthetic cross-linkers, through either the - or -subunit,
each had the desired covalent linkage (Fig. 1C, right
panel). Each of the dimers retained the ability to tightly bind
peptide antigen, as demonstrated by resistance to SDS-induced chain
dissociation (35) (Fig. 1C, left panel), and exhibited the
expected apparent molecular weight with no tendency to aggregate, as
determined by gel filtration chromatography (see below).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 1.
Cross-linking strategy for formation of
dimeric MHC-peptide complexes. A, synthetic
peptide-based cross-linking reagents used to make dimeric MHC-peptide
complexes. All cross-linkers carry a fluoresceinyl- -alanine
(FL- A) at the N terminus, and two maleimide
functional groups for coupling to HLA-DR1 cysteine residues. Estimated
maleimide to maleimide distances for these cross-linkers in fully
extended conformations are 50 Å (X3X), 70 Å (X9X), and 90 Å (X14X).
(For comparison, a disulfide-linked bond would have a length of ~2
Å.) B, ribbon diagram of the HLA-DR1-peptide complex (67),
showing the positions of introduced cysteine residues
(arrows). C, analysis of MHC-peptide dimers by
SDS-PAGE. Cross-linked MHC-peptide dimers form the expected disulfide
or covalent bond through either the alpha ( ) or beta ( ) subunit.
Left panel, nonreducing SDS-PAGE (12.5%) of purified
MHC-peptide dimers with samples not boiled before loading; the 
peptide complex stays associated in the absence of boiling (35),
indicating that cross-linking did not interfere with peptide binding.
Right panel, Reducing SDS-PAGE of boiled samples.
|
|
Effects of Receptor Orientation on CD4+ T-cell
Triggering--
The orientation dependence for T-cell activation was
investigated by comparing the dose-response curves of MHC dimers linked through the - or -subunit. MHC dimers were tested for their ability to trigger T-cell activation processes in HA1.7, a well characterized human T-cell clone (33) specific for an antigenic peptide
derived from influenza virus hemagglutinin (Ha) as presented by the
class II MHC protein HLA-DR1 (29). T-cells down-regulate engaged TCR
(CD3), as part of the activation process (36, 37). The down-modulation
of TCR in response to the soluble MHC dimers was measured by flow
cytometry using a PE-labeled antibody against the TCR CD3 subunit.
Disulfide-linked dimers of MHC proteins, complexed with Ha peptide and
cross-linked through either the - or -subunit
(Cys S-S and  Cys S-S), induced TCR
down-regulation in a dose-dependent manner (Fig.
2A, open and closed
circles). Dimers coupled with a long, flexible cross-linker
(Cys X14X and  Cys X14X,
open and closed squares), or dimers carrying the additional flexible connecting peptide linker on the -subunit ( L-Cys X14X, open diamonds) also induced
CD3 down-regulation. The level of activation induced by dimers linked
through either the - or -subunit was similar for complementary
pairs of disulfide-bonded dimers, and for complementary pairs of dimers
coupled through the peptide-based cross-linkers. As previously observed
(15, 27), neither MHC-peptide monomers (Fig. 2A, ×), nor
oligomers carrying the non-antigenic, endogenous peptide A2 (data not
shown), induced significant T-cell triggering in the concentration
range tested. Down-regulation of CD3 induced by the MHC dimers was
observed as early as 2 h and continued to increase over time, with
similar time courses for complementary dimers linked through the -
or -subunits (Fig. 2B). Collectively, these data
demonstrate that receptor orientation is not crucial for signaling, as
in each case dimers linked through the - or -subunit induced
T-cell activation to an equivalent extent.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 2.
Receptor orientation is not crucial for
CD4+ T-cell triggering. A, dose dependence
of HA1.7 T-cell triggering induced by MHC dimers as assayed by CD3/TCR
down-regulation after 20 h incubation. B, time course
of CD3 down-regulation induced with 0.16 µM of MHC dimer.
Dimers linked with direct disulfide bonds through the -subunit
(closed circles) or -subunit (open circles)
induce similar levels of T-cell activation. Dimers coupled with the
X14X cross-linker through the -subunit (closed squares),
-subunit (open squares), or -subunit containing the
connecting peptide region (open diamonds) are less efficient
at triggering activation than dimers linked through disulfide bonds.
Monomeric MHC-peptide complexes (×) do not trigger T-cell activation.
The left axis indicates mean PE-fluorescence measured by
flow cytometry for antibody against the CD3 subunit, the right
axis the corresponding number of TCR remaining on the cell
surface. Data are representative of several experiments performed on
HA1.7 T-cells.
|
|
Similar responses were observed for other measures of T-cell activation
processes, including up-regulation of the early T-cell activation
marker CD69 (38) (Fig. 3A),
up-regulation of the low-affinity IL-2 receptor -subunit (CD25) (39)
(Fig. 3B), and up-regulation of transferrin receptor (CD71)
(40) (Fig. 3C). In these assays, dimers with a range of
cross-linker lengths were used. For each T-cell activation marker
studied, MHC dimers coupled through the - or -subunit with direct
disulfide bonds (S-S) induced the most potent response. As the dimer
cross-linker length was increased, an incremental decrease in the
extent of T-cell activation was observed. Dimers coupled through
MHC-peptide complexes carrying the additional flexible connecting
peptide regions on the -subunit (LX14X) exhibited the least potent
activation. These data indicate a systematic activation dependence on
linker length, with only a slight dependence on inter-molecular
orientation.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
CD4+ T-cell triggering is
dependent on cross-linker length. Bars indicate levels
of T-cell activation induced by incubating 0.16 µM MHC
dimer with the HA1.7 T-cell clone as measured by: A, CD69
up-regulation after 12 h incubation; B, CD25 (IL-2R)
up-regulation after 36 h incubation; and C, CD71
(transferrin receptor) up-regulation after 60 h incubation.
Disulfide-bonded dimers (S-S) linked through the - or -subunit
provided the most potent stimulus. Increasing cross-linker length
resulted in decreasing levels of T-cell triggering for dimers linked
through either the - or -subunit. Error bars represent
replicates performed during the same experiment, and similar trends are
observed when experiments are performed on different days.
|
|
Effects of Orientation and Proximity on the Activation of a
Polyclonal T-cell Line--
To address whether the observed activation
responses were due to idiosyncratic aspects of the long-term T-cell
clone HA1.7, we repeated the activation experiments using a polyclonal
T-cell line raised from the peripheral blood of a DR1+
individual (designated 1H). The 1H polyclonal T-cell line exhibited CD3
down-regulation in response to MHC dimers, with dose-response curves
for disulfide-linked and X14X-linked MHC dimers (Fig.
4A) that were similar to those
observed for the HA1.7 T-cell clone. Activation of CD3 down-regulation
(Fig. 4B) and CD69 up-regulation (Fig. 4C) in the
1H polyclonal line were relatively independent of intermolecular
orientation, but were dependent on cross-linker length, with the
shortest cross-links (S-S) exhibiting the most potent signal, as
observed for the HA1.7 clone.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of orientation and proximity on the
activation of the 1H polyclonal T-cell line. A,
dose-response curves of CD3 down-regulation. B and
C, levels of CD3 down-regulation (B) and CD69
up-regulation (C) induced by 0.22 µM MHC
dimers. For the dose-response curves (A), CD3 levels were
measured after 6 h incubation. For the bar graphs
(B and C), CD3 and CD69 levels were measured
after 12 h incubation.
|
|
Correlation of Hydrodynamic Radii and T-cell Activation--
The
observed dependence of T-cell triggering on cross-linker length was
investigated in more detail. To evaluate the actual intermolecular
spacing in the intact oligomers, an apparent hydrodynamic radius was
characterized for each of the various dimers by gel filtration
chromatography (Fig. 5A). For
the Cys dimer series, a systematic dependence of
apparent hydrodynamic radius (RS) on cross-linker
length was observed (Table I), with
dimers coupled through short disulfide cross-links (S-S) exhibiting the
most compact conformation. Similar hydrodynamic behavior was observed for the  Cys dimer series (Table I). Dimers linked
through the -subunit exhibited slightly but systematically larger
apparent hydrodynamic radii than the corresponding dimers linked
through the -subunit. Plots of the apparent hydrodynamic radius
versus the T-cell response induced by the MHC dimers
exhibited a striking linear dependence. This dependence was observed in
the HA1.7 T-cell clone for CD3 down-regulation (Fig. 5B),
CD69 up-regulation (Fig. 5C), and CD25 up-regulation (Fig.
5D), and was also evident in the 1H polyclonal line (not
shown). Thus, T-cell activation is more efficiently triggered by more
compact dimers, for each of the responses studied.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Correlation of T-cell activation with
apparent hydrodynamic radii (RS).
A, gel filtration chromatography of MHC dimers. Apparent
molecular weights from gel filtration, with actual molecular masses in
parentheses: S-S, 94 ± 1 kDa (89,843); X3X, 99 ± 1 kDa
(91,380); X9X, 107 ± 0.4 kDa (91,926); X14X, 112 ± 1 kDa
(92,345). Confidence intervals (± ) reflect the standard
deviation from the mean of replicate samples in separate experiments.
Apparent hydrodynamic radii extracted from these data are shown in
Table I. B, C, and D, correlation of
apparent hydrodynamic radii (RS) with CD3
down-regulation (B), CD69 up-regulation (C), and
CD25 up-regulation (D) for the HA1.7 T-cell clone. The
linear relationship observed for each activation marker demonstrates a
dependence of T-cell triggering on dimer compactness. The correlation
coefficient (R2) is shown in each panel.
Activation data for CD69 and CD25 were taken from Fig. 3. Data for CD3
were obtained under similar conditions.
|
|
MHC Dimer Binding to T-cells--
The observed dependence of
T-cell triggering on linker length could possibly be due to decreased
binding for the dimers coupled through longer cross-links. To address
this possibility the relative binding of the MHC dimers was measured,
using a competitive binding assay in which unlabeled dimers compete for
the T-cell surface with streptavidin-linked, phycoerythrin-labeled
(SA-PE) MHC oligomers (34). MHC dimers linked through the -subunit
with the X3X, X9X, and X14X cross-linkers each exhibited essentially
identical competition curves (Fig.
6A), with half-maximal
inhibitions of ~0.3 µM. Dimers linked though the
-subunit with a direct disulfide bond (S-S) exhibited slightly
weaker binding, with a half-maximal inhibition of ~0.8
µM (Fig. 6A, filled circles). MHC dimers
linked through the -subunit with the X3X, X9X, and X14X
cross-linkers or direct disulfide bonds (S-S) bound similarly
(IC50 ~0.3 µM) (Fig. 6B).
Overall, the MHC dimers competed for binding more efficiently than
monomeric MHC-peptide complexes, which exhibited an IC50 of
~2.5 µM (Fig. 6A, ×), as previously
observed (15, 27). Since the competition curves for all of the MHC
dimers are similar, the decreased activation exhibited by MHC dimers
coupled through longer cross-linkers cannot be attributed to a
reduction in binding, and must be due to a decreased ability to trigger
T-cells once engaged to the receptor.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
MHC-peptide dimers bind similarly to
T-cells. Competitive binding assay of: A, -subunit;
and B, -subunit linked dimers. Varying concentrations of
MHC monomers and dimers were used to compete with phycoerythrin-labeled
MHC oligomers for binding to the HA1.7 T-cell clone: dimers linked
through the -subunit (closed symbols) or -subunit
(open symbols), with the X3X (inverted
triangles), X9X (triangles), X14X (squares)
cross-linkers; -linked dimers containing the connecting peptide
linker (open diamonds); and monomers (×). Most dimers
competed similarly for binding with a half-maximal inhibitory
concentration of ~0.3 µM. -Subunit dimers linked
through direct disulfide bonds (closed circles) competed
slightly worse for binding than the other dimers with a half-maximal
inhibitory concentration of ~0.8 µM. All dimers
competed better than MHC monomers, which had a half-maximal inhibition
of ~2.5 µM. Data are representative of several
experiments.
|
|
 |
DISCUSSION |
T-cell Triggering Is Not Dependent on Receptor Orientation--
We
have shown previously that CD4+ T-cells can be activated
with defined chemically coupled oligomers of MHC-peptide complexes (15,
27), extending earlier studies using other types of soluble MHC
oligomers (14, 41-44) or TCR cross-linking agents (6, 7, 20-22, 45).
It was determined that an MHC dimer was the minimal oligomer valency
sufficient to trigger several characteristic T-cell activation
processes (14, 15). In this report, we evaluated the constraints on
inter-molecular orientation and spacing within an activating MHC dimer.
We hypothesized that if T-cells were triggered by a mechanism that
relied on formation of a particular arrangement (or rearrangement) of
TCR in the membrane, then activation would be sensitive to the MHC
spacing and orientation within an activating dimer. However, if T-cells
were triggered by a generalized co-localization mechanism, activation
would be less dependent on the receptor orientation. This approach
follows one used previously to evaluate similar questions in the
erythropoietin receptor, in which a strong dependence on receptor
orientation was observed (46, 47). In the MHC/TCR system, we did not
observe a strong dependence on receptor orientation for initiation of
T-cell signaling. For each of several different cross-linkers,
conformationally constrained MHC dimers coupled through either the -
or the -subunit induced relatively similar levels of T-cell
activation, indicating that MHC orientation within the dimers was not
critical for activation. Similar results were observed for a polyclonal
culture of primary T-cells in addition to a long-term T-cell clone, and
for several markers of T-cell activation.
Since the first structural studies of class II MHC proteins, there has
been much speculation about the potential physiological relevance of a
class II MHC dimer observed in several crystal structures (1, 48-51).
In that dimer, the MHC molecules are arranged in a roughly parallel
manner with juxtaposed peptide-binding sites, and with -subunit C
termini that are substantially closer then the -subunit termini (13 versus 39 Å). This crystallographic orientation could be
adopted by any of the Cys -linked dimers, and possibly
by the  Cys dimers coupled through longer cross-links, but not by the disulfide-linked dimer  Cys S-S.
We observed that the  Cys S-S dimer was able to induce
T-cell activation, and in fact it was among the most potent dimers
tested herein. Thus, formation of the crystallographic MHC dimer is not
required for efficient T-cell triggering. Similarly, any T-cell
triggering mechanism that requires a particular receptor orientation
can be excluded, as the Cys S-S and
 Cys S-S dimers cannot both adopt the same
configuration without substantial unfolding, yet both trigger T-cell
activation with similar efficiency. These considerations suggest that
T-cell activation by MHC oligomers proceeds through a mechanism of
generalized receptor co-localization, and not through formation of a
particular activating receptor configuration.
T-cell Triggering Correlates with Receptor Proximity--
T-cell
triggering was dependent on the MHC cross-linker length, with the most
potent stimulus provided by MHC dimers linked through a short disulfide
bond. The degree of activation decreased monotonically as the length of
the linker was increased (Figs. 3 and 4), although the binding remained
constant (Fig. 6). These results indicate that inter-receptor proximity
is important in triggering T-cell activation processes. Cross-linking
strategies that constrained the MHC molecules to be closest together in
the most compact dimers were the most effective in activating T-cells, while MHC molecules coupled through longer cross-linkers were less
effective. This implies that for induction of T-cell activation by
soluble MHC oligomers, TCR complexes need to be brought closely together.
The earliest biochemical marker of T-cell activation is phosphorylation
of TCR cytoplasmic domains by membrane-associated Src family tyrosine
kinases (5). It is possible that clustering of receptor subunits by MHC
oligomers could trigger such phosphorylation events simply through a
mass action mechanism. In this scheme, TCR clustering would serve to
increase the local concentrations of receptor cytoplasmic domains and
tyrosine kinases, tipping the balance of kinases and phosphatases
toward phosphorylation of receptor-associated signaling proteins. For
example, a fraction of the total cellular tyrosine kinase Lck is found
associated with the cytoplasmic tail of CD4, a co-receptor for class II
molecules (52), and TCR clustering could facilitate receptor
phosphorylation by CD4-associated Lck. However, some T-cells can be
activated in the absence of CD4 (44), indicating a role for
CD4-independent signaling processes. We have proposed another possible
mechanism based on mass action (53), in which an increase in the local TCR concentration induces a conformational change in the TCR
-subunit cytoplasmic domain that allows phosphorylation by local
tyrosine kinases. In another possible mechanism, TCR clustering could
lead to phosphorylation through changes in the local receptor
environment. Relative to the bulk membrane around a resting TCR, the
membrane regions around clustered TCR might be enriched or depleted in particular lipids (54) and/or proteins (55) involved in the signaling
mechanism, leading to initiation of signaling processes around
clustered TCR. We have observed that multivalent engagement of TCR by
MHC oligomers is accompanied by cytoskeletal rearrangements and is
inhibited by disruption of lipid rafts (34), suggesting that receptors
can experience substantial alterations in their membrane environment
after clustering. Although these and other potential triggering
mechanisms remain to be definitively evaluated in the MHC/TCR system,
the results presented herein establish that any plausible model would
have to account for a lack of dependence on receptor orientation, but a
substantial dependence on receptor proximity.
T-cell Activation by Antigen-presenting Cells--
Our results
suggest that on a cellular level, the inter-receptor distances required
for T-cell activation by soluble MHC oligomers are very small. It is
not likely that specific MHC-peptide complexes would be found in such
proximity on the surface of an antigen-presenting cell, where MHC
proteins are bound to a wide spectrum of specific and nonspecific
peptides and distributed across the cell membrane. If T-cell activation
induced by antigen presenting cells proceeds similarly to
oligomer-induced activation, an active process may be required to
cluster the infrequent specific MHC-peptide complexes on the cell
surface to a density sufficient for TCR oligomerization (26, 56). Some
evidence has been presented in support of the existence of MHC
oligomers on the surface of antigen presenting cells prior to encounter
with a T-cell (51, 57-60). More recently, activated B cells have been
shown to cluster MHC-peptide complexes into lipid rafts (61), and
dendritic cells have been shown to transport MHC-rich vesicles from
endocytic compartments to the cell surface, forming semi-stable patches
rich in MHC-peptide complexes (62). In addition, processes involving
the T-cell could be responsible for this active clustering of
cell-surface components. Antigen-independent interactions of molecules
from both the antigen presenting cell and T-cell contribute to
efficient T-cell activation, in a process known as costimulation
(reviewed in Ref. 63). MHC/TCR binding with simultaneous ligation of
costimulatory molecules has been shown to stimulate an active,
cytoskeletal rearrangement of the cell surface molecules involved in
T-cell signaling, and appears to drive receptor accumulation at the
T-cell antigen-presenting cell interface (64).
Costimulation-dependent events that lead to TCR
localization at the cell-cell interface might play an important role in
lowering the TCR density required for cellular activation (65). Indeed,
saturating T-cell responses to MHC-peptide complexes incorporated into
planar bilayers in the absence of costimulation have been observed when
the average inter-receptor distance is ~200 Å or less (66), similar
to the MHC-to-MHC distances for the cross-links used in this study. By contrast, in the presence of costimulation the required density of MHC
peptide complexes incorporated into supported bilayers has been
reported to be ~60 molecules per µm2, corresponding to
an average distance of ~1800 Å between T-cell receptors (26). It
remains to be definitively established whether cytoskeletal
reorganizations induced by costimulation serve only to localize TCR to
a density required for efficient T-cell activation, or whether they
contribute to other events in the overall T-cell activation process.
Conclusion--
In summary, we have demonstrated that T-cell
activation by soluble MHC oligomers is not sensitive to inter-receptor
orientation, but does depend on receptor proximity. These results
suggest that the triggering mechanism involves a ligand-induced
oligomerization of TCR, and not a molecular rearrangement of a TCR
receptor oligomer. Furthermore, these results are consistent with a
transmembrane signaling mechanism that relies on co-localization of
receptor cytoplasmic domains, and not on formation of a particular TCR dimer in an activating conformation.
 |
ACKNOWLEDGEMENTS |
We thank Glen Paradis and the MIT Flow
Cytometry Core Facility for expert help in flow cytometry, Bader
Yassine-Diab for obtaining clinical samples, and Jennifer Zarutskie for
assistance with hydrodynamic calculations.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants N01AI95361 (to L. J. S.) and T32 GM08334 (to J. R. C., T. O. C., and J. D. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Current address: Dept. of Molecular Biophysics and Biochemistry,
Yale University, New Haven, CT 06527.
§
To whom correspondence should be addressed: Dept. of Chemistry,
Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA 02139. Tel.: 617-253-2849; Fax: 617-258-7847; E-mail: stern@mit.edu.
Published, JBC Papers in Press, May 30, 2001, DOI 10.1074/jbc.M103280200
 |
ABBREVIATIONS |
The abbreviations used are:
MHC, major
histocompatibility complex;
TCR, T-cell receptor;
RS, Stokes radius;
PAGE, polyacrylamide gel
electrophoresis;
IL, interleukin;
PE, phycoerythrin;
SA, streptavidin.
 |
REFERENCES |
| 1.
|
Germain, R. N.
(1994)
Cell
76,
287-299
|
| 2.
|
Hennecke, J.,
and Wiley, D. C.
(2001)
Cell
104,
1-4
|
| 3.
|
Ullman, K. S.,
Northrop, J. P.,
Verweij, C. L.,
and Crabtree, G. R.
(1990)
Annu. Rev. Immunol.
8,
421-452
|
| 4.
|
Glimcher, L. H.,
and Singh, H.
(1999)
Cell
96,
13-23
|
| 5.
|
Qian, D.,
and Weiss, A.
(1997)
Curr. Opin. Cell Biol.
9,
205-212
|
| 6.
|
Bekoff, M.,
Kubo, R.,
and Grey, H. M.
(1986)
J. Immunol.
137,
1411-1419
|
| 7.
|
Yoon, S. T.,
Dianzani, U.,
Bottomly, K.,
and Janeway, C. A., Jr.
(1994)
Immunity
1,
563-569
|
| 8.
|
Cochran, J. R.,
Aivazian, D. A.,
Cameron, T. O.,
and Stern, L. J.
(2001)
Trends Biochem. Sci.
26,
304-310
|
| 9.
|
Delon, J.,
Gregoire, C.,
Malissen, B.,
Darche, S.,
Lemaitre, F.,
Kourilsky, P.,
Abastado, J. P.,
and Trautmann, A.
(1998)
Immunity
9,
467-473
|
| 10.
|
Chambers, C. A.,
and Allison, J. P.
(1999)
Curr. Opin. Cell Biol.
11,
203-210
|
| 11.
|
Bachmann, M. F.,
and Ohashi, P. S.
(1999)
Immunol. Today
20,
568-576
|
| 12.
|
Sousa, J.,
and Carneiro, J.
(2000)
Eur. J. Immunol.
30,
3219-3227
|
| 13.
|
Fox, B. S.,
Quill, H.,
Carlson, L.,
and Schwartz, R. H.
(1987)
J. Immunol.
138,
3367-3374
|
| 14.
|
Boniface, J. J.,
Rabinowitz, J. D.,
Wulfing, C.,
Hampl, J.,
Reich, Z.,
Altman, J. D.,
Kantor, R. M.,
Beeson, C.,
McConnell, H. M.,
and Davis, M. M.
(1998)
Immunity
9,
459-466
|
| 15.
|
Cochran, J. R.,
Cameron, T. O.,
and Stern, L. J.
(2000)
Immunity
12,
241-250
|
| 16.
|
Hubbard, S. R.,
and Till, J. H.
(2000)
Annu. Rev. Biochem.
69,
373-398
|
| 17.
|
Falke, J. J.,
Bass, R. B.,
Butler, S. L.,
Chervitz, S. A.,
and Danielson, M. A.
(1997)
Annu. Rev. Cell Dev. Biol.
13,
457-512
|
| 18.
|
Klemm, J. D.,
Schreiber, S. L.,
and Crabtree, G. R.
(1998)
Annu. Rev. Immunol.
16,
569-592
|
| 19.
|
Jiang, G.,
and Hunter, T.
(1999)
Curr. Biol.
9,
R568-571
|
| 20.
|
Romeo, C.,
Amiot, M.,
and Seed, B.
(1992)
Cell
68,
889-897
|
| 21.
|
Letourneur, F.,
and Klausner, R. D.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
8905-8909
|
| 22.
|
Irving, B. A.,
and Weiss, A.
(1991)
Cell
64,
891-901
|
| 23.
|
San Jose, E.,
Sahuquillo, A. G.,
Bragado, R.,
and Alarcon, B.
(1998)
Eur. J. Immunol.
28,
12-21
|
| 24.
|
Fernandez-Miguel, G.,
Alarcon, B.,
Iglesias, A.,
Bluethmann, H.,
Alvarez-Mon, M.,
Sanz, E.,
and de la Hera, A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1547-1552
|
| 25.
|
Exley, M.,
Wileman, T.,
Mueller, B.,
and Terhorst, C.
(1995)
Mol. Immunol.
32,
829-839
|
| 26.
|
Grakoui, A.,
Bromley, S. K.,
Sumen, C.,
Davis, M. M.,
Shaw, A. S.,
Allen, P. M.,
and Dustin, M. L.
(1999)
Science
285,
221-227
|
| 27.
|
Cochran, J. R.,
and Stern, L. J.
(2000)
Chem. Biol.
7,
683-696
|
| 28.
|
Frayser, M.,
Sato, A. K.,
Xu, L.,
and Stern, L. J.
(1999)
Protein Expr. Purif.
15,
105-114
|
| 29.
|
Roche, P. A.,
and Cresswell, P.
(1990)
J. Immunol.
144,
1849-1856
|
| 30.
|
Chicz, R. M.,
and Strominger, J. L.
(1992)
Nature
358,
764-768
|
| 31.
|
Bubis, J.,
and Khorana, H. G.
(1990)
J. Biol. Chem.
265,
12995-12999
|
| 32.
|
Zarutskie, J. A.,
Sato, A. K.,
Rushe, M. M.,
Chan, I. C.,
Lomakin, A.,
Benedek, G. B.,
and Stern, L. J.
(1999)
Biochemistry
38,
5878-5887
|
| 33.
|
Lamb, J. R.,
Eckels, D. D.,
Lake, P.,
Woody, J. N.,
and Green, N.
(1982)
Nature
300,
66-69
|
| 34.
|
Cameron, T. O.,
Cochran, J. R.,
Yassine-Diab, B.,
Sekaly, R.-P.,
and Stern, L. J.
(2001)
J. Immunol.
166,
741-745
|
| 35.
|
Stern, L. J.,
and Wiley, D. C.
(1992)
Cell
68,
465-477
|
| 36.
|
Itoh, Y.,
Hemmer, B.,
Martin, R.,
and Germain, R. N.
(1999)
J. Immunol.
162,
2073-2080
|
| 37.
|
Valitutti, S.,
Muller, S.,
Cella, M.,
Padovan, E.,
and Lanzavecchia, A.
(1995)
Nature
375,
148-151
|
| 38.
|
Testi, R.,
D'Ambrosio, D.,
De Maria, R.,
and Santoni, A.
(1994)
Immunol. Today
15,
479-483
|
| 39.
|
Waldmann, T. A.
(1989)
Annu. Rev. Biochem.
58,
875-911
|
| 40.
|
Ponka, P.,
and Lok, C. N.
(1999)
Int. J. Biochem. Cell Biol.
31,
1111-1137
|
| 41.
|
Casares, S.,
Zong, C. S.,
Radu, D. L.,
Miller, A.,
Bona, C. A.,
and Brumeanu, T. D.
(1999)
J. Exp. Med.
190,
543-554
|
| 42.
|
Abastado, J. P.,
Lone, Y. C.,
Casrouge, A.,
Boulot, G.,
and Kourilsky, P.
(1995)
J. Exp. Med.
182,
439-447
|
| 43.
|
Appel, H.,
Gauthier, L.,
Pyrdol, J.,
and Wucherpfennig, K. W.
(2000)
J. Biol. Chem.
275,
312-321
|
| 44.
|
Hamad, A. R.,
O'Herrin, S. M.,
Lebowitz, M. S.,
Srikrishnan, A.,
Bieler, J.,
Schneck, J.,
and Pardoll, D.
(1998)
J. Exp. Med.
188,
1633-1640
|
| 45.
|
Spencer, D. M.,
Wandless, T. J.,
Schreiber, S. L.,
and Crabtree, G. R.
(1993)
Science
262,
1019-1024
|
| 46.
|
Syed, R. S.,
Reid, S. W.,
Li, C.,
Cheetham, J. C.,
Aoki, K. H.,
Liu, B.,
Zhan, H.,
Osslund, T. D.,
Chirino, A. J.,
Zhang, J.,
Finer-Moore, J.,
Elliott, S.,
Sitney, K.,
Katz, B. A.,
Matthews, D. J.,
Wendoloski, J. J.,
Egrie, J.,
and Stroud, R. M.
(1998)
Nature
395,
511-516
|
| 47.
|
Livnah, O.,
Johnson, D. L.,
Stura, E. A.,
Farrell, F. X.,
Barbone, F. P.,
You, Y.,
Liu, K. D.,
Goldsmith, M. A.,
He, W.,
Krause, C. D.,
Pestka, S.,
Jolliffe, L. K.,
and Wilson, I. A.
(1998)
Nat. Struct. Biol.
5,
993-1004
|
| 48.
|
Brown, J. H.,
Jardetzky, T. S.,
Gorga, J. C.,
Stern, L. J.,
Urban, R. G.,
Strominger, J. L.,
and Wiley, D. C.
(1993)
Nature
364,
33-39
|
| 49.
|
Fields, B. A.,
and Mariuzza, R. A.
(1996)
Immunol. Today
17,
330-336
|
| 50.
|
Schafer, P. H.,
Pierce, S. K.,
and Jardetzky, T. S.
(1995)
Semin. Immunol.
7,
389-398
|
| 51.
|
Triantafilou, K.,
Triantafilou, M.,
and Fernandez, N.
(2000)
Crit. Rev. Immunol.
20,
359-373
|
| 52.
|
Janeway, C. A., Jr.
(1992)
Annu. Rev. Immunol.
10,
645-674
|
| 53.
|
Aivazian, D.,
and Stern, L. J.
(2000)
Nat. Struct. Biol.
7,
1023-1026
|
| 54.
|
Langlet, C.,
Bernard, A. M.,
Drevot, P.,
and He, H. T.
(2000)
Curr. Opin. Immunol.
12,
250-255
|
| 55.
|
van der Merwe, P. A.,
Davis, S. J.,
Shaw, A. S.,
and Dustin, M. L.
(2000)
Semin. Immunol.
12,
5-21
|
| 56.
|
Reay, P. A.,
Matsui, K.,
Haase, K.,
Wulfing, C.,
Chien, Y. H.,
and Davis, M. M.
(2000)
J. Immunol.
164,
5626-5634
|
| 57.
|
Schafer, P. H.,
Malapati, S.,
Hanfelt, K. K.,
and Pierce, S. K.
(1998)
J. Immunol.
161,
2307-2316
|
| 58.
|
Roucard, C.,
Garban, F.,
Mooney, N. A.,
Charron, D. J.,
and Ericson, M. L.
(1996)
J. Biol. Chem.
271,
13993-14000
|
| 59.
|
Cherry, R. J.,
and Fernandez, N.
(1998)
J. Cell Biol.
140,
71-79
|
| 60.
|
Triantafilou, K.,
Triantafilou, M.,
Wilson, K. M.,
and Fernandez, N.
(2000)
Hum. Immunol.
61,
585-598
|
| 61.
|
Anderson, H. A.,
Hiltbold, E. M.,
and Roche, P. A.
(2000)
Nat. Immunol.
1,
156-162
|
| 62.
|
Turley, S. J.,
Inaba, K.,
Garrett, W. S.,
Ebersold, M.,
Unternaehrer, J.,
Steinman, R. M.,
and Mellman, I.
(2000)
Science
288,
522-527
|
| 63.
|
Chambers, C. A.
(2001)
Trends Immunol.
22,
217-223
|
| 64.
|
Wulfing, C.,
and Davis, M. M.
(1998)
Science
282,
2266-2269
|
| 65.
|
Viola, A.,
and Lanzavecchia, A.
(1996)
Science
273,
104-106
|
| 66.
|
Watts, T. H.
(1988)
J. Immunol.
141,
3708-3714
|
| 67.
|
Stern, L. J.,
Brown, J. H.,
Jardetzky, T. S.,
Gorga, J. C.,
Urban, R. G.,
Strominger, J. L.,
and Wiley, D. C.
(1994)
Nature
368,
215-221
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Anikeeva, T. Lebedeva, A. R. Clapp, E. R. Goldman, M. L. Dustin, H. Mattoussi, and Y. Sykulev
Quantum dot/peptide-MHC biosensors reveal strong CD8-dependent cooperation between self and viral antigens that augment the T cell response
PNAS,
November 7, 2006;
103(45):
16846 - 16851.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Horii, M. L. Kahn, and A. B. Herr
Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI
Blood,
August 1, 2006;
108(3):
936 - 942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. S. Angelov, P. Guillaume, M. Cebecauer, G. Bosshard, D. Dojcinovic, P. Baumgaertner, and I. F. Luescher
Soluble MHC-Peptide Complexes Containing Long Rigid Linkers Abolish CTL-Mediated Cytotoxicity
J. Immunol.,
March 15, 2006;
176(6):
3356 - 3365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Sulchek, R. W. Friddle, K. Langry, E. Y. Lau, H. Albrecht, T. V. Ratto, S. J. DeNardo, M. E. Colvin, and A. Noy
Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds
PNAS,
November 15, 2005;
102(46):
16638 - 16643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cebecauer, P. Guillaume, S. Mark, O. Michielin, N. Boucheron, M. Bezard, B. H. Meyer, J.-M. Segura, H. Vogel, and I. F. Luescher
CD8+ Cytotoxic T Lymphocyte Activation by Soluble Major Histocompatibility Complex-Peptide Dimers
J. Biol. Chem.,
June 24, 2005;
280(25):
23820 - 23828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Buatois, M. Baillet, S. Becart, N. Mooney, L. Leserman, and P. Machy
MHC Class II-Peptide Complexes in Dendritic Cell Lipid Microdomains Initiate the CD4 Th1 Phenotype
J. Immunol.,
December 1, 2003;
171(11):
5812 - 5819.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|